On February 25, 2016, the Board of Directors of Hemispherx Biopharma, Inc. appointed Thomas K. Equels, the current President of the company, as the company's Chief Executive Officer. In that capacity, he is the principal executive officer of the company.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3727 USD | -4.44% |
|
-9.19% | -15.28% |
06-05 | Transcript : AIM ImmunoTech Inc. - Special Call | |
05-16 | Transcript : AIM ImmunoTech Inc., Q1 2024 Earnings Call, May 16, 2024 |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.28% | 21.29M | |
+15.20% | 121B | |
+19.67% | 113B | |
+18.95% | 26.02B | |
-23.86% | 19.39B | |
-19.03% | 15.91B | |
-20.90% | 15.09B | |
-46.14% | 15.06B | |
+63.85% | 14.93B | |
+4.49% | 13.85B |
- Stock Market
- Equities
- AIM Stock
- News AIM ImmunoTech Inc.
- Hemispherx Biopharma, Inc. Appoints Thomas K. Equels as Chief Executive Officer